Choose Site

Press Release

Morgan Lewis Advises Bristol Myers Squibb in Research Collaboration with Repare Therapeutics

May 29, 2020

PRINCETON, May 29, 2020: Morgan Lewis represented Bristol Myers Squibb in its worldwide research collaboration agreement with Repare Therapeutics to identify multiple oncology drug candidates.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Repare is a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations.

Partners David Glazer, Alan Leeds, and Harry Robins, and associate Michael Chang represented Bristol Myers Squibb.

For more, read the announcement.